CN Patent

CN102481330A — C型利钠肽变体

Assigned to Biomarin Pharmaceutical Inc · Expires 2012-05-30 · 14y expired

What this patent protects

本申请公开文本提供一种C型利钠肽(CNP)的变体、包含CNP变体的医药组合物，及制造CNP变体的方法。这些CNP变体适用于治疗CNP反应性疾病的治疗剂，这些疾病包括(但不限于)骨相关病症，诸如骨骼发育不良(例如软骨发育不全)，及血管平滑肌病症(例如再狭窄及动脉硬化)。

USPTO Abstract

本申请公开文本提供一种C型利钠肽(CNP)的变体、包含CNP变体的医药组合物，及制造CNP变体的方法。这些CNP变体适用于治疗CNP反应性疾病的治疗剂，这些疾病包括(但不限于)骨相关病症，诸如骨骼发育不良(例如软骨发育不全)，及血管平滑肌病症(例如再狭窄及动脉硬化)。

Drugs covered by this patent

Patent Metadata

Patent number
CN102481330A
Jurisdiction
CN
Classification
—
Expires
2012-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.